Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;5(2):499-520.
doi: 10.1007/s13300-014-0087-6. Epub 2014 Nov 4.

Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries

Victoria Divino  1 , Mitch DeKoven, Shawn Hallinan, Nebibe Varol, Sara Bruce Wirta, Won Chan Lee, Matthew Reaney
Affiliations

Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries

Victoria Divino et al. Diabetes Ther. 2014 Dec.

Abstract

Introduction: The objective of this study was to evaluate real-world treatment patterns of type 2 diabetes (T2D) patients initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Germany (GE), the United Kingdom (UK), France (FR), the Netherlands (NE), Belgium (BE), and Sweden (SE).

Methods: Adult T2D patients initiating exenatide twice daily (exBID), liraglutide once daily (LIRA) or exenatide once weekly (exQW) were identified using the IMS LifeLink™ (IMS Health, Danbury, CT, USA): Electronic Medical Records (EMR; GE/UK/FR) and IMS LifeLink™: longitudinal prescriptions (LRx; NE/BE/GE/UK) databases, and national health register data (SE), between 2010 and 2012. Therapy initiation date was termed 'index date'. Eligible patients had ≥180-day pre- and variable follow-up (minimum ≥360-day post-index exBID and LIRA, ≥180-day post-index exQW). Treatment modification and persistence were evaluated over 180 days. Kaplan-Meier (KM) survival curves and Cox proportional hazards models (PHMs; EMR databases only) evaluated stopping of the index therapy (measured as first of discontinuation or switch).

Results: 30,206 exBID, 5,401 exQW, and 52,155 LIRA patients were included in the analysis (46.0-66.9% male; mean age range 55.4-59.3 years). Mean follow-up was 20.3-27.4 months for exBID and LIRA, and 7.6-13.9 months for exQW. Across the databases, the proportion experiencing a treatment modification at 180 days was highest among exBID (37.6-81.7%) compared to LIRA (36.8-56.6%) and exQW (32.3-47.7%). The proportion persistent at 180 days was lowest among exBID patients (46.8-73.5%) compared to LIRA (50.6-80.1%) or exQW (57.5-74.6%). In the KM analyses, LIRA patients had a lower proportion stopping therapy at all time points compared to exBID patients, across the databases. In the Cox PHMs, LIRA was associated with a significantly lower risk of stopping compared to exBID; in GE, exQW was associated with a lower risk compared to exBID and LIRA.

Conclusion: Treatment patterns varied among GLP-1 RA patients, with persistence highest among either LIRA or exQW across countries, and lowest among exBID. Longer-term data would be useful, particularly given limited exQW follow-up due to more recent launch.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier analyses for time to stop: a exBID, b exQW, c LIRA. Patient-level analysis was not possible with the UK LRx due to privacy legislation; therefore, treatment pattern outcomes were not assessed. BE Belgium, EMR Electronic Medical Records databases, exBID exenatide twice daily, exQW exenatide once weekly, FR France, GE Germany, LIRA liraglutide once daily, LRx Longitudinal Prescriptions databases, NE The Netherlands, SE Sweden, UK United Kingdom
See this image and copyright information in PMC

References

    1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels: International Diabetes Federation; 2013. http://www.idf.org/diabetesatlas. Accessed February 18, 2014.
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35:1364–1379. doi: 10.2337/dc12-0413. - DOI - PMC - PubMed
    1. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370:794–797. doi: 10.1056/NEJMp1314078. - DOI - PubMed
    1. Byetta: EPAR—European Medicines Agency—Europa, European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Infor... (2011). Accessed March 28, 2013.
    1. Victoza: EPAR—Product Information—European Medicines Agency. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Infor... (2014). Accessed October 21, 2014.